Paradoxical Reactions to Anti-TNFa and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F23%3A00571652" target="_blank" >RIV/61388971:_____/23:00571652 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064211:_____/23:W0000026

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s13555-023-00904-4" target="_blank" >https://link.springer.com/article/10.1007/s13555-023-00904-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13555-023-00904-4" target="_blank" >10.1007/s13555-023-00904-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Paradoxical Reactions to Anti-TNFa and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Popis výsledku v původním jazyce

Psoriasis is a chronic, immune-mediated, inflammatory disease primarily affecting the skin. It is currently coming to light that patients with psoriasis have disrupted intestinal barrier and often suffer from comorbidities associated with the gastrointestinal tract. Moreover, there is growing evidence of both cutaneous and intestinal paradoxical reactions during biologic treatment in patients with psoriasis. This review focuses on barrier defects and changes in immune responses in patients with psoriasis, which play an important role in the development of the disease but are also influenced by modern biological treatments targeting IL-17 and TNF alpha cytokines. Here, we highlight the relationship between the gut-skin axis, microbiota, psoriasis treatment, and the incidence of paradoxical reactions, such as inflammatory bowel disease in patients with psoriasis. A better understanding of the interconnection of these mechanisms could lead to a more personalized therapy and lower the incidence of treatment side effects, thereby improving the quality of life of the affected patients.

Název v anglickém jazyce

Paradoxical Reactions to Anti-TNFa and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Popis výsledku anglicky

Psoriasis is a chronic, immune-mediated, inflammatory disease primarily affecting the skin. It is currently coming to light that patients with psoriasis have disrupted intestinal barrier and often suffer from comorbidities associated with the gastrointestinal tract. Moreover, there is growing evidence of both cutaneous and intestinal paradoxical reactions during biologic treatment in patients with psoriasis. This review focuses on barrier defects and changes in immune responses in patients with psoriasis, which play an important role in the development of the disease but are also influenced by modern biological treatments targeting IL-17 and TNF alpha cytokines. Here, we highlight the relationship between the gut-skin axis, microbiota, psoriasis treatment, and the incidence of paradoxical reactions, such as inflammatory bowel disease in patients with psoriasis. A better understanding of the interconnection of these mechanisms could lead to a more personalized therapy and lower the incidence of treatment side effects, thereby improving the quality of life of the affected patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatology and Therapy

ISSN

2193-8210

e-ISSN

2190-9172

Svazek periodika

13

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

23

Strana od-do

911-933

Kód UT WoS článku

000952922700001

EID výsledku v databázi Scopus

2-s2.0-85150022380